Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

The brawl over redistricting is handing Gov. Gavin Newsom his biggest platform yet ahead of a likely presidential run in 2028 ...

That was when the Chino High School student, a Dreamer, learned an immigration judge had effectively shelved his deportation ...

Your guide to federal funding cuts, plus resources for farmers and food businesses seeking support and solutions.

Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized -- LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and ...